IR@PKUHSC  > 北京大学临床肿瘤学院  > 淋巴肿瘤内科
学科主题临床医学
Single nucleotide polymorphisms of CD20 gene and their relationship with clinical efficacy of R-CHOP in patients with diffuse large B cell lymphoma
Ding, Huirong1; Jin, Xuan2; Ding, Ning3; Fu, Zhiying3; Song, Yuqin3; Zhu, Jun3
刊名CANCER CELL INTERNATIONAL
2013-06-10
DOI10.1186/1475-2867-13-58
13
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]ANTI-CD20 MONOCLONAL-ANTIBODY ; NON-HODGKINS-LYMPHOMA ; RITUXIMAB ; MUTATIONS ; THERAPY ; IDEC-C2B8 ; REGIMENS ; RECEPTOR ; TARGET
英文摘要

Background: R-CHOP has significantly improved survival rates of patients with diffuse large B cell lymphoma (DLBCL) by similar to 20% as compared to CHOP. CD20 antigen, highly expressed on more than 80% of B-cell lymphomas, is the target for rituximab. The goal of our study was to examine polymorphism in the CD20 gene in Chinese DLBCL population and whether CD20 gene polymorphism is associated with clinical response to R-CHOP.

Method: CD20 gene polymorphism was detected in the entire coding regions including 6 exons by polymerase chain reaction (PCR)-sequencing assay in 164 patients with DLBCL. Among them, 129 patients treated with R-CHOP as frontline therapy (R >= 4 cycles) were assessable for the efficacy.

Results: Polymorphisms at three single nucleotides (SNP) were identified in the entire coding regions of the CD20 gene in the 164 patients. One of them, CD20 Exon2 ([216]) was found to be highly correlated with response to R-CHOP. Patients with homozygous C genotype showed a trend toward higher overall response rate than others with CT plus TT genotype (90.6% vs. 79.5%; P = 0.166). A trend toward higher complete remission (CR) rate was observed in patients with homozygous C genotype (67.4%) compared with CT plus TT genotype (47.1%) (P = 0.091).

Conclusion: These results suggest that there are 3 SNPs in CDS of the CD20 gene in Chinese DLBCL population. The CC genotype at Exon2 ([216]) appears to be associated with favourable response to R-CHOP.

语种英语
WOS记录号WOS:000320605700001
项目编号30973484
资助机构National Natural Science Foundation of China
引用统计
被引频次:5[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/68059
专题北京大学临床肿瘤学院_淋巴肿瘤内科
北京大学第一临床医学院_肿瘤化疗科
北京大学临床肿瘤学院_中心实验室
作者单位1.Peking Univ, Canc Hosp & Inst, Cent Lab, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
2.Peking Univ, Hosp 1, Dept Internal Med Oncol, Beijing 100034, Peoples R China
3.Peking Univ, Canc Hosp & Inst, Dept Lymphom, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
推荐引用方式
GB/T 7714
Ding, Huirong,Jin, Xuan,Ding, Ning,et al. Single nucleotide polymorphisms of CD20 gene and their relationship with clinical efficacy of R-CHOP in patients with diffuse large B cell lymphoma[J]. CANCER CELL INTERNATIONAL,2013,13.
APA Ding, Huirong,Jin, Xuan,Ding, Ning,Fu, Zhiying,Song, Yuqin,&Zhu, Jun.(2013).Single nucleotide polymorphisms of CD20 gene and their relationship with clinical efficacy of R-CHOP in patients with diffuse large B cell lymphoma.CANCER CELL INTERNATIONAL,13.
MLA Ding, Huirong,et al."Single nucleotide polymorphisms of CD20 gene and their relationship with clinical efficacy of R-CHOP in patients with diffuse large B cell lymphoma".CANCER CELL INTERNATIONAL 13(2013).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Ding, Huirong]的文章
[Jin, Xuan]的文章
[Ding, Ning]的文章
百度学术
百度学术中相似的文章
[Ding, Huirong]的文章
[Jin, Xuan]的文章
[Ding, Ning]的文章
必应学术
必应学术中相似的文章
[Ding, Huirong]的文章
[Jin, Xuan]的文章
[Ding, Ning]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。